Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Department of Chemical and Geological Sciences, University of Cagliari, Cagliari, Italy.
Molecules. 2019 Jun 26;24(13):2367. doi: 10.3390/molecules24132367.
Lymphoma defines a group of different diseases. This study examined pre-treatment plasma samples from 66 adult patients (aged 20-74) newly diagnosed with any lymphoma subtype, and 96 frequency matched population controls. We used gas chromatography-mass spectrometry (GC-MS) to compare the metabolic profile by case/control status and across the major lymphoma subtypes. We conducted univariate and multivariate analyses, and partial least square discriminant analysis (PLS-DA). When compared to the controls, statistically validated models were obtained for diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and Hodgkin lymphoma (HL), but not follicular lymphoma (FL). The metabolomic analysis highlighted interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects: Important metabolites, such as hypoxanthine and elaidic acid, were more abundant in all lymphoma subtypes. The small sample size of the individual lymphoma subtypes prevented obtaining PLS-DA validated models, although specific peculiar features of each subtype were observed; for instance, fatty acids were most represented in MM and HL patients, while 2-aminoadipic acid, 2-aminoheptanedioic acid, erythritol, and threitol characterized DLBCL and CLL. Metabolomic analysis was able to highlight interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects. Further studies are warranted to understand whether the peculiar metabolic patterns observed might serve as early biomarkers of lymphoma.
淋巴瘤定义了一组不同的疾病。本研究检测了 66 名新诊断为任何淋巴瘤亚型的成年患者（年龄 20-74 岁）和 96 名频数匹配的人群对照的治疗前血浆样本。我们使用气相色谱-质谱联用（GC-MS）技术比较了病例/对照状态和主要淋巴瘤亚型之间的代谢谱。我们进行了单变量和多变量分析以及偏最小二乘判别分析（PLS-DA）。与对照组相比，弥漫性大 B 细胞淋巴瘤（DLBCL）、慢性淋巴细胞白血病（CLL）、多发性骨髓瘤（MM）和霍奇金淋巴瘤（HL）获得了统计学上验证的模型，但滤泡性淋巴瘤（FL）则没有。代谢组学分析突出了淋巴瘤患者与人群对照之间的有趣差异，允许在病理和健康受试者之间进行区分：重要的代谢物，如次黄嘌呤和反油酸，在所有淋巴瘤亚型中更为丰富。个别淋巴瘤亚型的小样本量阻止了获得 PLS-DA 验证模型的获得，尽管观察到了每个亚型的特定特征；例如，脂肪酸在 MM 和 HL 患者中最为代表，而 2-氨基己二酸、2-氨基庚二酸、赤藓糖醇和苏糖醇则是 DLBCL 和 CLL 的特征。代谢组学分析能够突出淋巴瘤患者与人群对照之间的有趣差异，允许在病理和健康受试者之间进行区分。需要进一步的研究来了解观察到的特殊代谢模式是否可以作为淋巴瘤的早期生物标志物。
